FDA Exploring Over-the-Counter Access to Vaginal Estrogen
The FDA says it is working with sponsors to explore over-the-counter availability of vaginal estrogen. Here’s what that could mean for vaginal dryness and other menopause symptoms.
The FDA says it is working with sponsors to explore over-the-counter availability of vaginal estrogen. Here’s what that could mean for vaginal dryness and other menopause symptoms.
HHS announced that the FDA approved updated labeling for three more estradiol patch products, removing boxed warning statements, and gave an update on hormone therapy supply and access.
An executive order signed October 19, 2026 creates a Women’s Health Division at NIH and a White House Women’s Health Task Force, and names menopause among the areas needing more research.
ACOG issued its most comprehensive menopause guidance yet, strongly recommending hormone therapy for hot flashes and sleep problems and expanding advice on nonhormonal treatments, mood and sleep.
The American College of Physicians issued a new guideline recommending estrogen-based hormone therapy as first-line treatment for menopausal hot flashes and night sweats, with ranked nonhormonal alternatives.
The FDA held a public workshop on testosterone use in menopausal women. No testosterone product is approved for women, and the comment period has closed. Here’s what was discussed and what comes next.
The FDA has approved Lynkuet (Elinzanetant), a groundbreaking non-hormonal medication that targets the brain pathways behind hot flashes. For women who can’t or prefer not to use hormone therapy, this represents a major step forward in menopause care.
UK approves first testosterone cream for postmenopausal women—sparking hope for future FDA approval in the U.S.
Elinzanetant (Lynkuet) is a new non-hormonal therapy under FDA review that could finally provide relief from hot flashes for women who can’t or prefer not to take hormone therapy. Promising trial results offer hope for midlife symptom relief.
Fezolinetant (Veozah) is the first non-hormonal drug approved to tackle menopausal hot flashes—but a rare liver injury warning means careful monitoring is essential. Could this new option finally provide relief for women who can’t or don’t want hormone therapy?
A major 2024 review of the Women’s Health Initiative has rewritten the story on hormone therapy. For women under 60 or within 10 years of menopause, the benefits may outweigh the risks—marking a turning point in how doctors and patients approach treatment.
Could a weekly pill shift the menopause timeline? Researchers are exploring how one drug might change the future of women’s health.